The HPV vaccine is one of the most effective cancer-preventing tools in modern medicine. In clinical trials, the current nine-strain vaccine (Gardasil 9) proved 96.7% effective at preventing cervical, vulvar, and vaginal disease caused by the strains it targets. Real-world data from nearly 1.7 million women in Sweden showed that girls vaccinated before age 17 had a nearly 90% reduction in cervical cancer incidence over an 11-year period.
How Well It Prevents Cervical Cancer
The strongest evidence comes from population-level studies tracking vaccinated and unvaccinated women over many years. In the large Swedish study, after adjusting for factors that influence cervical cancer risk, vaccinated women had a 63% lower chance of being diagnosed with cervical cancer overall. That number jumped to nearly 90% among those vaccinated before age 17, highlighting why early vaccination matters so much.
The vaccine also prevents the precancerous changes that develop years before cancer itself. A meta-analysis of 11 studies covering more than 21,000 people found that HPV vaccination reduced the risk of high-grade precancerous cervical lesions by 65%. These lesions are the ones that, left untreated, most commonly progress to invasive cancer. Catching fewer of them means fewer biopsies, fewer surgical procedures, and far less anxiety for patients.
What the Vaccine Protects Against
Gardasil 9 covers nine strains of human papillomavirus. Two of those strains (HPV 16 and 18) cause roughly 70% of all cervical cancers. Five additional strains (31, 33, 45, 52, and 58) account for another 20% of cervical cancers. The final two strains (6 and 11) are the main causes of genital warts rather than cancer. Altogether, the vaccine targets about 90% of the HPV strains responsible for cervical cancer.
HPV doesn’t only cause cervical cancer. It’s also linked to cancers of the throat, anus, penis, vulva, and vagina. Among vaccinated age groups, oropharyngeal (throat and mouth) cancer rates are projected to nearly halve between 2018 and 2045. Researchers estimate that by 2045, roughly 1,000 cases of oropharyngeal cancer will be prevented each year in the United States alone.
Benefits for Men
HPV vaccination isn’t just for women. Men develop HPV-related cancers of the throat, anus, and penis, and oropharyngeal cancer has been rising sharply in men over recent decades. Because these cancers take decades to develop, the full impact of male vaccination won’t be visible for 25 or more years. But modeling studies project meaningful drops in cancer rates among well-vaccinated age groups over the coming decades.
Australia’s experience offers a preview. After the country introduced female-only vaccination in 2007, genital warts among young women aged 15 to 20 plummeted from 9.8% to about 1% within just a few years. When Australia expanded the program to include boys in 2013, genital warts dropped an additional 16% among young men. These fast-moving results reflect how quickly the vaccine works against the wart-causing strains, even though cancer prevention takes longer to measure.
Herd Protection for Unvaccinated People
One of the vaccine’s most remarkable effects is protecting people who never received it. When enough people in a community are vaccinated, the virus has fewer hosts to circulate through, which shields unvaccinated individuals too. A pooled analysis of 16 transmission models projected that even at 40% vaccination coverage, HPV-16 prevalence drops by 53% after several decades. At 80% coverage, that reduction reaches 93%.
A comprehensive review of 65 studies across 14 high-income countries confirmed these herd effects in real populations: unvaccinated men and older women in countries with high vaccine uptake saw significant reductions in genital warts and HPV infections. In Sweden, unvaccinated women born during the era of school-based vaccination programs had substantially fewer high-grade cervical lesions than unvaccinated women from earlier cohorts. The vaccine, in other words, changes the landscape for everyone.
How Long Protection Lasts
Long-term follow-up studies have now tracked vaccinated women for up to 14 years. A Nordic study found 100% vaccine effectiveness against high-grade cervical changes for at least 12 years, with a clear trend toward continued protection through the full 14-year follow-up period. Antibody levels remained stable throughout, and there was no evidence of waning immunity. No booster dose has been recommended.
The CDC confirms that protection lasts more than 10 years without becoming less effective. Since the vaccine has only existed since 2006, researchers can’t yet say whether immunity lasts a lifetime, but everything observed so far points toward very durable protection.
One Dose May Be Enough
The original HPV vaccination schedule required three doses. That was later reduced to two for people starting before age 15. Now, evidence is building that a single dose works nearly as well. A clinical trial of more than 20,000 girls aged 12 to 16 in Costa Rica found that one dose provided protection against persistent HPV infections that was statistically no worse than two doses. Both vaccines tested were at least 97% effective at preventing persistent HPV 16 and 18 infections, whether given as one dose or two.
This finding has major implications for global vaccination efforts. The World Health Organization updated its recommendations to include a single-dose option, which makes the vaccine cheaper, simpler to deliver, and more accessible in countries where multi-dose schedules are hard to complete.
Why Age at Vaccination Matters
The vaccine works best when given before any exposure to HPV, which is why it’s recommended starting at age 9 to 12. The nearly 90% reduction in cervical cancer seen in the Swedish study applied specifically to girls vaccinated before 17. Those vaccinated later still benefited, but the protection was smaller, reflected in the 63% overall reduction across all ages.
This isn’t because the vaccine is weaker in older people. It’s because someone vaccinated at 20 or 25 may have already been exposed to one or more HPV strains, reducing the number of new infections the vaccine can prevent. For people who missed the ideal window, vaccination up to age 26 is routinely recommended, and it’s approved for adults up to 45 who discuss the potential benefits with their healthcare provider. Even for someone already treated for precancerous cervical changes, getting vaccinated afterward reduces the risk of recurrence.